Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations
Tóm tắt
Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti–PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair–deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti–PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Significance: A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188–201. ©2016 AACR.
See related commentary by Marabelle et al., p. 128.
This article is highlighted in the In This Issue feature, p. 115
Từ khóa
Tài liệu tham khảo
Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011
Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904
Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082
Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087
Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093
Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596
Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824
Nghiem, 2016, PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma, N Engl J Med, 374, 2542, 10.1056/NEJMoa1603702
Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nature reviews Cancer, 12, 252, 10.1038/nrc3239
Taube, 2012, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689
Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954
Ribas, 2015, Adaptive immune resistance: how cancer protects from immune attack, Cancer Discov, 5, 915, 10.1158/2159-8290.CD-15-0563
Bach, 1997, The IFN gamma receptor: a paradigm for cytokine receptor signaling, Annu Rev Immunol, 15, 563, 10.1146/annurev.immunol.15.1.563
Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958
Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, 3, 991, 10.1038/ni1102-991
Kaplan, 1998, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proc Natl Acad Sci U S A, 95, 7556, 10.1073/pnas.95.13.7556
Mazzolini, 2003, Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis, Gene Ther, 10, 1067, 10.1038/sj.gt.3301957
Gao, 2016, Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 Therapy, Cell, 167, 397, 10.1016/j.cell.2016.08.069
Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348
Hugo, 2016, Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma, Cell, 165, 35, 10.1016/j.cell.2016.02.065
Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4
Rodig, 1998, Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses, Cell, 93, 373, 10.1016/S0092-8674(00)81166-6
Muller, 1993, The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction, Nature, 366, 129, 10.1038/366129a0
Watling, 1993, Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway, Nature, 366, 166, 10.1038/366166a0
Barretina, 2012, The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003
Ren, 2013, JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations, Scientific reports, 3, 3042, 10.1038/srep03042
Platanias, 2005, Mechanisms of type-I- and type-II-interferon-mediated signalling, Nat Rev Immunol, 5, 375, 10.1038/nri1604
Fish, 2014, Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes, Mol Cancer Res, 12, 1691, 10.1158/1541-7786.MCR-14-0450
Dunn, 2005, IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression, Cancer Res, 65, 3447, 10.1158/0008-5472.CAN-04-4316
Spranger, 2015, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404
Ribas, 2016, Association of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA, 315, 1600, 10.1001/jama.2016.4059
Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626
Atefi, 2014, Effects of MAPK and PI3K Pathways on PD-L1 expression in melanoma, Clin Cancer Res, 20, 3446, 10.1158/1078-0432.CCR-13-2797
Wong, 2014, Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma, Mol Cancer, 13, 194, 10.1186/1476-4598-13-194
Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624
Kotecha, 2010, Web-based analysis and publication of flow cytometry experiments, Current protocols in cytometry/editorial board, 10.1002/0471142956.cy1017s53
Escuin-Ordinas, 2014, COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors, Mol Oncol, 8, 250, 10.1016/j.molonc.2013.11.005
Shi, 2014, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy, Cancer Discov, 4, 80, 10.1158/2159-8290.CD-13-0642
Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol, 31, 213, 10.1038/nbt.2514
Koboldt, 2012, VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing, Genome research, 22, 568, 10.1101/gr.129684.111
Ramos, 2015, Oncotator: cancer variant annotation tool, Human mutation, 36, E2423, 10.1002/humu.22771
McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490
Favero, 2015, Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data, Ann Oncol, 26, 64, 10.1093/annonc/mdu479
Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095
Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088